Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOOM
ABAHF =CHEAPEST CBD Company
ABAHF= Market Cap $49 M - Cash $28 M -Shares Out 11 M --GREAT CBD products and Close to profitability =STRONG BUY TGT $15-20 .GL
Buy Abacus Health Products for CBD exposure, says Beacon Securities
https://www.cantechletter.com/2019/12/buy-abacus-health-products-for-cbd-exposure-says-beacon-securities/
That’s according to Beacon Securities analyst Doug Cooper who launched coverage of the stock on Tuesday with a “Buy” rating and C$15.00 target price, saying that investors might also be interested in Abacus as a possible takeout target.
Valuation: C$308m or C$14.26 per basic share
https://www.edisongroup.com/publication/selling-cbd-the-right-way/25582/
Abacus Health posts 3Q revenue of $4.1 million, boosts pharmacy presence
https://www.proactiveinvestors.com/companies/news/907671/abacus-health-posts-3q-revenue-of-41-million-boosts-pharmacy-presence-907671.html
ABAHF =CHEAPEST CBD Company
ABAHF= Market Cap $49 M - Cash $28 M -Shares Out 11 M --GREAT CBD products and Close to profitability =STRONG BUY TGT $15-20 .GL
Buy Abacus Health Products for CBD exposure, says Beacon Securities
https://www.cantechletter.com/2019/12/buy-abacus-health-products-for-cbd-exposure-says-beacon-securities/
That’s according to Beacon Securities analyst Doug Cooper who launched coverage of the stock on Tuesday with a “Buy” rating and C$15.00 target price, saying that investors might also be interested in Abacus as a possible takeout target.
Valuation: C$308m or C$14.26 per basic share
https://www.edisongroup.com/publication/selling-cbd-the-right-way/25582/
Abacus Health posts 3Q revenue of $4.1 million, boosts pharmacy presence
https://www.proactiveinvestors.com/companies/news/907671/abacus-health-posts-3q-revenue-of-41-million-boosts-pharmacy-presence-907671.html
LIFETIME OPP at this ultra low price
RSLS= MC $3 M / Cash $7.7 M / O/S only 353K / Obesity treatment marketed Worldwide (BILLION $ Market)/Strong Insider Ownership /UNKNOWN gem = 10+ BAGGER GEM....
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
RSLS ..Nasdaq Uplisting coming but this super extreme low float gem likely to explode higher before the uplist thats why now is a great entry point .GL
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
"Achieve revenues and profits to meet criteria for NASDAQ listing"
RSLS..Close up 44% on friday and its still a PURE GIFT at $3.3 Million valaution ...
RSLS= MC $2 M / Cash $7.7 M / O/S only 353K over 200k of these shares owned by Armistice / Obesity treatment marketed Worldwide (BILLION $ Market) /UNKNOWN gem =This extreme low float gem could be MORE than just a 10 bagger
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
Nasdaq Uplisting and Profitability on the way
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
"Achieve revenues and profits to meet criteria for NASDAQ listing"
RSLS
RSLS =MC $2 M /O/S 353 K / Cash $7.7M-- this SUPER EXTREME low float is close to profitability . Lap band to treat Obesity is marketed international. This unknown gem is a potential $100 stock trading at laughable $5.50.A MONSTER Opp here guys
ReShape Lifesciences, Inc. is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape VestTM*, an investigational device, to help treat more patients with obesity.
Reshape Lifescience (RSLS)
Market Cap: $2 M
Cash: $7.7 M
Price $6
Shares Out: 353K << over 200k shares owned by Armistice
Revenue expected to be around $15 million --Product Lap band aquired december 2018 -- lap Band was owned by Allergan at its Peak the product hit almost $300 Million
MASSIVE insider buying
https://www.secform4.com/insider-trading/1371217.htm
presentation
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
•Acquired in December 2018
•Global regulatory approval
•Only obesity device reimbursed in U.S.
•High-margin product, maintained ASP
•Focus commercial organization on strategic markets for LAP-BAND® •Drive revenue utilizing new long-term clinical data and patient marketing
•Achieve revenues and profits to meet criteria for NASDAQ listing
MONSTER Rally could start anytime now ..ONLY 353K outstanding shares and most of these shares held by Armistice (60%) alone .Thisextremely low float gem could explode like a nuclear bomb
RSLS =MC $2 M -Shares OUT 353 K most of these shares held by Amristice who continue buying more shares .. RSLS is a undiscovered stock the company has a obesity treatment on the markets worldwide which they aquired 13 months ago sales already on track to hit $15 million . the product was owned by Allergan and they reached $290 million in revenue at its peak so only half of that would make RSRS worth hundred of millions currently trading at laughable $2 million .
Stock is close to expolode
STRONG BUY
$100 stocktraind at $6.50
attractive takeover candidate
great buying opp
RSLS =MC $2 M /O/S 353 K / Cash $7.7M-- this SUPER EXTREME low float is close to profitability . Lap band to treat Obesity is marketed international. This unknown gem is a potential $100 stock trading at laughable $5.50.A MONSTER Opp here guys
ReShape Lifesciences, Inc. is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape VestTM*, an investigational device, to help treat more patients with obesity.
Reshape Lifescience (RSLS)
Market Cap: $2 M
Cash: $7.7 M
Price $6
Shares Out: 353K << over 200k shares owned by Armistice
Revenue expected to be around $15 million --Product Lap band aquired december 2018 -- lap Band was owned by Allergan at its Peak the product hit almost $300 Million
MASSIVE insider buying
https://www.secform4.com/insider-trading/1371217.htm
presentation
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
•Acquired in December 2018
•Global regulatory approval
•Only obesity device reimbursed in U.S.
•High-margin product, maintained ASP
•Focus commercial organization on strategic markets for LAP-BAND® •Drive revenue utilizing new long-term clinical data and patient marketing
•Achieve revenues and profits to meet criteria for NASDAQ listing
RSLS=Only 100K Shrs in float could go to $50+ very fast onceit gets noticed
RSLS =MC $1.8 M /O/S 353 K / Cash $7.7M-- this SUPER EXTREME low float is close to profitability . Lap band to treat Obesity is marketed international. This unknown gem is a potential $100 stock trading at laughable $5.50.A MONSTER Opp here guys
ReShape Lifesciences, Inc. is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape VestTM*, an investigational device, to help treat more patients with obesity.
Reshape Lifescience (RSLS)
Market Cap: $1.8 M
Cash: $7.7 M
Shares Out: 353K << over 200k shares owned by Armistice
Revenue expected to be around $15 million --Product Lap band aquired december 2018 -- lap Band was owned by Allergan at its Peak the product hit almost $300 Million
MASSIVE insider buying
https://www.secform4.com/insider-trading/1371217.htm
presentation
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
•Acquired in December 2018
•Global regulatory approval
•Only obesity device reimbursed in U.S.
•High-margin product, maintained ASP
•Focus commercial organization on strategic markets for LAP-BAND® •Drive revenue utilizing new long-term clinical data and patient marketing
•Achieve revenues and profits to meet criteria for NASDAQ listing
RSLS =MC $1.8 M /O/S 353 K / Cash $7.7M-- this SUPER EXTREME low float is close to profitability . Lap band to treat Obesity is marketed international. This unknown gem is a potential $100 stock trading at laughable $5.50.A MONSTER Opp here guys
ReShape Lifesciences, Inc. is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. Our current portfolio includes the LAP-BAND® Adjustable Gastric Banding System and the ReShape VestTM*, an investigational device, to help treat more patients with obesity.
Reshape Lifescience (RSLS)
Market Cap: $1.8 M
Cash: $7.7 M
Shares Out: 353K << over 200k shares owned by Armistice
Revenue expected to be around $15 million --Product Lap band aquired december 2018 -- lap Band was owned by Allergan at its Peak the product hit almost $300 Million
MASSIVE insider buying
https://www.secform4.com/insider-trading/1371217.htm
presentation
https://ir.reshapelifesciences.com/static-files/b1a15609-3950-47ad-b00f-ef8430fd1a30
•Acquired in December 2018
•Global regulatory approval
•Only obesity device reimbursed in U.S.
•High-margin product, maintained ASP
•Focus commercial organization on strategic markets for LAP-BAND® •Drive revenue utilizing new long-term clinical data and patient marketing
•Achieve revenues and profits to meet criteria for NASDAQ listing
CANF =Market Cap $9 M -O/S 4 M -Phase 2 readout of NASH trial IIMMINENT--Additional 3 Drugs in Phase 3 =Could be a 10 Bagger and more expecially on positive outcome of the Nash trial .GL
Fact Sheet (good infos)
https://content.equisolve.net/canfite/media/da26e454bef851b0c93729dbceda9a01.pdf
CANF = UP 6% in Pre-Mkt,, extreme low floater with major news around the corner like the NASH phase 2 readout coming any day now (expected for this Quarter)
CANF =Market Cap $9 M -O/S 4 M -Phase 2 readout of NASH trial IIMMINENT--Additional 3 Drugs in Phase 3 =Could be a 10 Bagger and more expecially on positive outcome of the Nash trial .GL
https://content.equisolve.net/canfite/media/da26e454bef851b0c93729dbceda9a01.pdf
low float rocket with great pipeline
NASH Phase 2 results imminent
cheap
CANF =MC $9 M -O/S 4 M -Phase 2 readout of NASH trial IIMMINENT--Additional 3 Drugs in Phase 3 =1000%+ GEM ..LIFETIME OPP
https://content.equisolve.net/canfite/media/da26e454bef851b0c93729dbceda9a01.pdf
(CANF)Mkt-Cap $9 M--O/S 4 M -Phase 2 readout of NASH trial IIMMINENT--Additional 3 Drugs in Phase 3 =2000%++ GEM ..LIFETIME OPP
https://content.equisolve.net/canfite/media/da26e454bef851b0c93729dbceda9a01.pdf
CANF= MC $10 M -- O/S 4 M-- 3x Phase 3 trials / Phase 2 results (NASH) imminent.. Potential 10+ bagger gem here guys
https://content.equisolve.net/canfite/media/da26e454bef851b0c93729dbceda9a01.pdf
CANF =MC $9 M --NASH P2 DATA imminent ($25+ BILLION MKT with NO approved treatment to date = Could be more than just a 10 bagger aMEGA opp here guys .GL
https://ir.canfite.com/press-releases/detail/881/can-fite-ceo-issues-letter-to-shareholders
Q1 2020: Topline results from NASH Phase II study expected
Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing distribution agreements
Two Phase III studies enrolling in psoriasis and rheumatoid arthritis
CANF =MC $9 M --NASH P2 DATA imminent ($25+ BILLION MKT with NO approved treatment to date = Could be more than just a 10 bagger aMEGA opp here guys .GL
https://ir.canfite.com/press-releases/detail/881/can-fite-ceo-issues-letter-to-shareholders
Q1 2020: Topline results from NASH Phase II study expected
Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing distribution agreements
Two Phase III studies enrolling in psoriasis and rheumatoid arthritis
CHMA = Great News out ...Stock is up 10% could double or triple ahead of the upcoming FDA decision in mid of the year
CHMA =MC $200 M--Cash $103 M -- FIRST & ONLY oral drug for the treatment of acromegaly close to US approval (likely in June/July) a potential BLOCKBUSTER =500%++ GEM
https://static2.seekingalpha.com/uploads/sa_presentations/545/48545/slides/31.jpg?1573069031
Chiasma Provides Corporate Update and Previews 2020 Milestones...January 10, 2020
https://finance.yahoo.com/news/chiasma-provides-corporate-previews-2020-120010135.html
CHMA = Great News out ...Stock is up 10% could double or triple ahead of the upcoming FDA decision in mid of the year
CHMA =MC $200 M--Cash $103 M -- FIRST & ONLY oral drug for the treatment of acromegaly close to US approval (likely in June/July) a potential BLOCKBUSTER =500%++ GEM
https://static2.seekingalpha.com/uploads/sa_presentations/545/48545/slides/31.jpg?1573069031
Chiasma Provides Corporate Update and Previews 2020 Milestones...January 10, 2020
https://finance.yahoo.com/news/chiasma-provides-corporate-previews-2020-120010135.html
TNXP ..Great buying opp again
valuation of $13 million is still under Cash balance of $18 million and two phase 3 readouts on the way with first phase 3 interim data coming any day now (during Q1) .Still a Super Strong Buy